We are live on ! Find out more
SCM

SKBA Capital Management Portfolio holdings

AUM $728M
1-Year Est. Return 12.18%
This Fund
S&P 500
This Quarter Est. Return
+20.14%
1 Year Est. Return
+12.18%
3 Year Est. Return
+52.29%
5 Year Est. Return
+76.86%
10 Year Est. Return
+235.51%
AUM
$597M
AUM Growth
+$96M
Cap. Flow
+$4.99M
Cap. Flow %
0.84%
Top 10 Hldgs %
28.32%
Holding
80
New
8
Increased
30
Reduced
24
Closed
4

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.19M
2
CB icon
Chubb
CB
+$5.75M
3
CAH icon
Cardinal Health
CAH
+$5.55M
4
CME icon
CME Group
CME
+$5.51M
5
VTRS icon
Viatris
VTRS
+$5.16M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.85M
2
KMB icon
Kimberly-Clark
KMB
+$5.32M
3
CVS icon
CVS Health
CVS
+$4.92M
4
ETN icon
Eaton
ETN
+$4.86M
5
INTC icon
Intel
INTC
+$4.83M

Sector Composition

Rank Sector Weight
1 Financials 19.94%
2 Healthcare 16%
3 Industrials 11.27%
4 Consumer Staples 9.47%
5 Energy 9.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GE icon
76
GE Aerospace
GE
$384B
$116K 0.02%
2,147
CVS icon
77
CVS Health
CVS
$122B
-84,300
Closed -$4.92M
GILD icon
78
Gilead Sciences
GILD
$165B
-108,400
Closed -$6.85M
KMB icon
79
Kimberly-Clark
KMB
$36.5B
-36,020
Closed -$5.32M
VLO icon
80
Valero Energy
VLO
$85.9B
-8,050
Closed -$349K

Similar funds

SKBA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, SKBA Capital Management held 80 positions worth $597M, up 19% from $501M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

SKBA Capital Management's Q4 2020 filing shows 8 new, 30 increased, 24 reduced and 4 closed positions. Its largest new stake was CME Group: 32,400 shares worth $5.9M. The largest sale was Gilead Sciences, an estimated $6.85M.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.

  • SKBA Capital Management's largest Q4 2020 buy was CME Group: 32,400 shares worth $5.9M.
  • SKBA Capital Management added most to Merck in Q4 2020, an estimated $9.19M increase.
  • SKBA Capital Management's biggest Q4 2020 reduction was Eaton, cutting an estimated $4.86M.
  • SKBA Capital Management fully exited Gilead Sciences in Q4 2020, selling an estimated $6.85M.
  • SKBA Capital Management's ten largest holdings make up 28% of its $597M portfolio in Q4 2020.
  • SKBA Capital Management opened 8 new positions and closed 4 in Q4 2020.
  • SKBA Capital Management's portfolio value rose 19% quarter-over-quarter to $597M.

Based on SKBA Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.